Answer
Remdesivir is converted within host cells to an active triphosphate that competes with ATP for incorporation into SARS-CoV-2 RNA, causing delayed chain termination, and can also inhibit RNA synthesis when incorporated into template viral RNA by impairing complementary nucleotide incorporation.
Sources for this answer
- Veklury 100 mg powder for concentrate for solution for infusionGilead Sciences Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 26Document updated
Sources checked